Shanghai Pharma's Digoxin Tablets Pass Generic Drug Equivalence Assessment

Stock News04-08

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd., has received the "Drug Supplement Application Approval Notice" (Notice No.: 2026B01912) from the National Medical Products Administration for its Digoxin Tablets, indicating that the product has passed the generic drug consistency evaluation. Digoxin Tablets are indicated for: 1. Treating mild to moderate heart failure in adults. Digoxin can increase left ventricular ejection fraction and improve heart failure symptoms, demonstrated by enhanced exercise capacity and reduced hospitalizations and emergency treatments related to heart failure, without affecting mortality. When possible, digoxin should be used in combination with diuretics and angiotensin-converting enzyme (ACE) inhibitors. 2. Increasing myocardial contractility in pediatric patients with heart failure. 3. Controlling ventricular rate in patients with atrial fibrillation or atrial flutter accompanied by rapid ventricular rate, as well as supraventricular tachycardia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148842109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148842109","market":"us","top_or_hot":-1,"title":"Shanghai Pharma's Digoxin Tablets Pass Generic Drug Equivalence Assessment","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd., has received the \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B01912) from the National Medical Products Administration for its Digoxin Tablets, indicating that the product has passed the generic drug consistency evaluation. Digoxin Tablets are indicated for: 1. Treating mild to moderate heart failure in adults. Digoxin can increase left ventricular ejection fraction and improve heart failure symptoms, demonstrated by enhanced exercise capacity and reduced hospitalizations and emergency treatments related to heart failure, without affecting mortality. When possible, digoxin should be used in combination with diuretics and angiotensin-converting enzyme (ACE) inhibitors. 2. Increasing myocardial contractility in pediatric patients with heart failure. 3. Controlling ventricular rate in patients with atrial fibrillation or atrial flutter accompanied by rapid ventricular rate, as well as supraventricular tachycardia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharma's Digoxin Tablets Pass Generic Drug Equivalence Assessment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharma's Digoxin Tablets Pass Generic Drug Equivalence Assessment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-08 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd., has received the \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B01912) from the National Medical Products Administration for its Digoxin Tablets, indicating that the product has passed the generic drug consistency evaluation. Digoxin Tablets are indicated for: 1. Treating mild to moderate heart failure in adults. Digoxin can increase left ventricular ejection fraction and improve heart failure symptoms, demonstrated by enhanced exercise capacity and reduced hospitalizations and emergency treatments related to heart failure, without affecting mortality. When possible, digoxin should be used in combination with diuretics and angiotensin-converting enzyme (ACE) inhibitors. 2. Increasing myocardial contractility in pediatric patients with heart failure. 3. Controlling ventricular rate in patients with atrial fibrillation or atrial flutter accompanied by rapid ventricular rate, as well as supraventricular tachycardia.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1148842109","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148842109","pubTimestamp":1775635824,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd., has received the \"Drug Supplement Application Approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0209":"零售","BK0187":"一线龙头","BK0184":"上海国资改革","BK0028":"国家队","BK0099":"上海本地重组","02607":"上海医药","BK0097":"医药电商","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"上药地高辛片通过仿制药等效性评价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd., has received the \"Drug Supplement Application Approval Notice\" (Notice No.: 2026B01912) from the National Medical Products Administration for its Digoxin Tablets, indicating that the product has passed the generic drug consistency evaluation. Digoxin Tablets are indicated for: 1. Treating mild to moderate heart failure in adults. Digoxin can increase left ventricular ejection fraction and improve heart failure symptoms, demonstrated by enhanced exercise capacity and reduced hospitalizations and emergency treatments related to heart failure, without affecting mortality. When possible, digoxin should be used in combination with diuretics and angiotensin-converting enzyme (ACE) inhibitors. 2. Increasing myocardial contractility in pediatric patients with heart failure. 3. Controlling ventricular rate in patients with atrial fibrillation or atrial flutter accompanied by rapid ventricular rate, as well as supraventricular tachycardia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148842109","isCrawlerRequest":true}